GLUT1

BAY-876 is an orally active, selective inhibitor of glucose transporter 1 (GLUT1, IC50= 2 nM), exhibiting over 130-fold greater selectivity for GLUT1 than GLUT2, GLUT3, and GLUT4. It also inhibits glycolytic metabolism and ovarian cancer growth.

Marein shows neuroprotective effect on PC12 cell damage induced by methylglyoxal, which is due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway, it may be a potent compound for preventing counteracting diabetic e

WZB117 is a Glucose Transporter 1 (GLUT1) inhibitor. when IC50 of WZB117 approximate 10 μM, it inhibits lung cancer A549 cells and breast cancer MCF7 cells proliferation.

GLUT1-IN-3 (Compd 4b), a compound under investigation for type 1 glucose transporter deficiency syndrome, effectively inhibits seizures [1].

KL-11743 specifically blocks glucose metabolism, triggering an acute collapse in NADH pools and a striking accumulation of aspartate, indicating a dramatic shift toward oxidative phosphorylation in the mitochondria.

GLUT1 EGFR-IN-1 (compound H) is a potent inhibitor of both GLUT1 and EGFR. It targets the ATP-binding site of the EGFR tyrosine kinase and inhibits GLUT1-mediated energy metabolism, resulting in reduced ATP, MMP, intracellular lactate, and nuclear translocation of EGFR. GLUT1 EGFR-IN-1 is applicable in the research of nasopharyngeal carcinoma (NPC) and triple-negative breast cancer (TNBC).

GLUT1-IN-1, a glucose transporter 1 (GLUT1) inhibitor, possesses specific inactivation capability for GLUT1. This compound demonstrates concentration-dependent cytotoxicity towards HeLa, A549, and HepG2 cells, with IC50 values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. It is utilized in the research of photodynamic therapy (PDT) and several cancers [1].

STF-31 is an inhibitor of glucose transporter 1 (GLUT1) with IC50 of 1 μM.

Triheptanoin (IND 106011) is a fatty acid metabolic modulator. It potentially for the treatment of fatty acid oxidation disorders and GLUT1.

hydrocotarnine is an inhibitor of Cbl.

NV-5440 is a novel cell penetrant, potent and selective class I glucose transporters (GLUT1) inhibitor, selectively inhibiting mTORC1

GLUT4-IN-2 is a specific GLUT4 inhibitor that inhibits GLUT1 and GLUT4.GLUT4-IN-2 has antitumor activity, induces apoptosis and cell cycle arrest, and can be used for cancer research.

Glutor, a selective GLUT 1 2 3 inhibitor, inhibits glucose uptake, suppresses glycolysis, and effectively induces the death of cancer cells cultured in monolayers and spheroids [1].

AS1949490 activated glucose metabolism via up-regulation of GLUT1 gene in L6 myotubes[1][2]. AS1949490 is a potent and selective SHIP-2 (SH2 domain-containing inositol 5′ phosphatase 2) inhibitor, with an IC50 of 620 nM.

4,6-O-Ethylidene-α-D-glucose (Ethylidene-glucose), a derivative of glucose, serves as a competitive inhibitor for the exofacial binding site of glucose transporter 1 (GLUT1), exhibiting a Ki of 12 mM against wild-type 2-deoxy-D-glucose transport.

Fasentin (N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide) is an inhibitor of GluT1.

GLUT inhibitor-1 is an orally active GLUT inhibitor with IC50 s of 242 nM and 179 nM for GLUT1 and GLUT3. GLUT inhibitor-1 can be used in studies about cancers and autoimmune diseases.

(Rac)-Glutipyran is a broad-spectrum GLUT inhibitor targeting both GLUT1 and GLUT3. This compound inhibits glucose uptake and significantly impedes the growth of various cancer cells, particularly demonstrating substantial inhibition of PANC-1 cell growth (IC50=1.8 μM) and glucose uptake (IC50=0.13 μM).

BAY-588 is an inactive control probe of BAY-876 which is an inhibitor of GLUT1.

AS1938909 is a SHIP2 inhibitor that works by increasing Akt phosphorylation, glucose consumption, and glucose uptake in L6 myotubes, specifically upregulating the GLUT1 gene.

Lavendustin B is a Tyrosine Kinase Inhibitor and an inhibitor of HIV-1 integrase (IN) interaction with its cognate cellular cofactor, lens epithelium-derived growth factor (LEDGF p75).